Benefit-Risk (B-R) Assessment in Pharmacovigilance

Assess benefit risk in pharmacovigilance by weighing favorable effects against adverse effects, across licensing and post-approval life cycles, with patient, physician, and pharmacist interactions.

Explore how new products, diverse data sources, and advanced benefit-risk methods drive transparent, structured pharmacovigilance in complex biologics and vaccines.

Explore international benefit risk initiatives and standardized methodologies, including ICH M4 R2 and E2 R2 guidelines, and the roles of FDA, EMA, and cross-border collaborations in pharmacovigilance.

Define the structured benefit risk framework and its purpose for evaluating medicinal products. Explain components like key benefits, key risks, risk management, trade-offs, and quantitative methodologies.

Explore popular benefit-risk frameworks like Brad and Proact URL, showing how to define context, build the value tree, identify data sources, and display key benefit-risk matrices.

Explore the structured benefit risk framework components: product opportunity, product profile, and risk management—documenting therapeutic context, disease conditions, current treatments, and CIOMS WG12–aligned risk–benefit conclusions across the product life cycle.

Identify the product profile and key benefits and risks using a value tree to inform the benefit risk assessment and the Brad document.

Explore risk management in pharmacovigilance, detailing risk characterization, uncertainty assessment, pharmacovigilance planning, and risk minimization to maintain a favorable benefit risk balance across populations.

Explore patient’s role in the structured benefit risk framework, showing how patient and carer input improves evidence quality, decision making, transparency, and understanding of outcomes, safety, and quality of life.

Identify when additional quantitative analysis is required in benefit-risk assessment, such as marginal trade-offs or high uncertainties, and apply modeling or Monte Carlo simulation to estimate efficacy and safety.

Explore the benefit–risk assessment methodologies across medicinal products, medical devices, diagnostics, procedures, and consumer therapies, and learn how treatment environment and patient factors shape the overall BRA.

Explore generalizability, intention-to-treat concepts, and absolute versus relative risk to improve benefit-risk assessment in pharmacovigilance, emphasizing pre-specified endpoints, pragmatic, patient-centric approaches, and handling cumulative effects and competing risks.

Integrate benefit-risk into the clinical trial lifecycle by defining endpoints in design, monitoring with a DMC, analyzing results, and transparently reporting in literature and registries, including subgroups and intention-to-treat considerations.

Explore quantitative benefit–risk assessment methods, including multi-criteria decision analysis, stochastic multicriteria acceptability analysis, Monte Carlo simulation, number needed to treat, number needed to harm, and benefit–risk ratio.

Gain patient insights to strengthen benefit-risk assessment in pharmacovigilance throughout pre- and post-authorization, guiding study design, endpoints, regulatory review, and risk management.

Explore visualization approaches for benefit-risk assessments using attribute trees and effect tables, and apply forest, waterfall, heat map, and tornado plots to convey key benefits and risks to stakeholders.

Explore how the multidisciplinary brmt drives benefit risk assessment across the product life cycle through signal validation, cross-functional reviews, and regulatory decisions by senior leadership.

Discover Brad, the company benefit-risk assessment document, and how it captures unmet patient needs, target populations, key benefits and risks, and mitigation strategies across the product life cycle.

See a practical demo of the benefit risk assessment document (brad) for pharmacovigilance, detailing cover page, executive summary, benefit risk tables, risk management, and annexures.

Explore benefit-risk assessment in pharmacovigilance for special situations with limited information, and apply real life monitoring, simulation techniques, extrapolation, data synthesis, and post-marketing monitoring to address uncertainty.

Conclude your benefit-risk assessment in pharmacovigilance training by retrieving your certificate and sharing it on LinkedIn. Access downloadable resources and explore courses in signal detection, aggregate reporting, and risk management.